[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2023 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

October 2017 | 202 pages | ID: TCB57A763DBEN
GlobalData

US$ 4,995.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2023 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

SUMMARY

Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia - high blood glucose levels - that results from defects in insulin secretion, insulin action, or a combination of these. Chronic hyperglycemia is associated with the long-term damage, dysfunction and failure of multiple organs including the eyes, kidneys, nerves, heart and blood vessels. Prevalence of the disease has risen rapidly in recent decades in the assessed South-East Asia countries, primarily as a result of rising obesity, a major risk factor for type 2 diabetes mellitus (T2DM). This has resulted in a large and competitive market landscape, with a number of drugs vying for various market segments across multiple lines of therapy.

T2DM treatment has been revolutionized in the past decade, especially with the increased use of new therapies. The marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, and insulin therapies. Nevertheless, significant unmet need remains for products that can offer better glycemic control, as well as the prevention and cure of diabetic complications, such as diabetic nephropathy, retinopathy, and cardiovascular disease.

SCOPE

The current T2DM market in South-East Asia contains novel products, including Jardiance, a SGLT-2 inhibitor; Victoza, a GLP-1 receptor agonist; and Januvia, a DPP-4 inhibitor.
  • What are the competitive advantages of the existing novel drugs?
There are over 609 active pipeline molecules, with most of the late-stage investigational drug candidates featuring improved dosing regimens and administration routes compared with currently marketed products and combination therapies.
  • Which classes of novel drugs are most prominent in the pipeline?
  • Is there potential for pipeline molecules to address unmet needs within the T2DM market?
Analysis of clinical trials since 2006 identified that the failure rates of T2DM molecules were highest in Phase III, at 62.1%, with the overall attrition rate for T2DM standing at 88.3%.
  • How do failure rates vary by product stage of development, molecule type, and mechanism of action?
  • How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?
Over the 2016-2023 forecast period, the T2DM therapeutics market in South-East Asia is expected to increase in value at a CAGR of 6.3%, from $1.92 billion to over $2.96 billion.
  • Which markets make the most significant contribution to the regional market size?
  • What are the epidemiology trends in these markets?
  • Will new market entrants lead to substantial changes in annual therapy costs?
  • How will different treatment usage patterns impact growth in the eight assessed South-East Asia markets?
Rising T2DM prevalence and the uptake of newer therapies will lead to significant market growth over the forecast period, despite generic sales erosion resulting from patent expirations.
  • Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?
REASONS TO BUY
  • Understand the clinical context of T2DM by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
  • Identify the therapeutic strategies, products, and companies that dominate the current marketed product landscape and recognize gaps and areas of unmet need.
  • Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
  • Consider market opportunities and potential risks by examining trends in T2DM clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
  • Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in T2DM by examining clinical trial data and multi-scenario product forecast projections.
  • Compare treatment usage patterns, annual therapy costs, and market growth projections for South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia.
  • Discover trends in licensing and co-development deals concerning T2DM products, and identify the major strategic consolidations that have shaped the commercial landscape.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 Disease Introduction
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology and Pathophysiology
2.5 Diagnosis
2.6 Classification
2.7 Prognosis
2.8 Treatment Options
  2.8.1 Treatment Algorithm
  2.8.2 Non-insulin T2DM Therapies
  2.8.3 Insulin T2DM Therapies
2.9 Treatment Segments
  2.9.1 Non-Insulin Therapies
  2.9.2 Insulin Therapies
2.10 Co-morbidities and Complications
2.11 Non-pharmacological Treatments
  2.11.1 Dietary Interventions
  2.11.2 Exercise

3 MARKETED PRODUCTS

3.1 Overview
3.2 Biguanides
  3.2.1 Metformin
3.3 Sulfonylureas
3.4 Thiazolidinediones
  3.4.1 Pioglitazone
  3.4.2 Duvie (lobeglitazone) - Chong Kun Dang
3.5 GLP-1 Receptor Agonists
  3.5.1 Byetta (exenatide) - AstraZeneca
  3.5.2 Bydureon (exenatide) - AstraZeneca
  3.5.3 Victoza (liraglutide) - Novo Nordisk
  3.5.4 Lyxumia (lixisenatide) - Sanofi
  3.5.5 Tanzeum (albiglutide) - GlaxoSmithKline
  3.5.6 Trulicity (dulaglutide) - Eli Lilly
3.6 DPP-4 Inhibitors
  3.6.1 Januvia (sitagliptin) - Merck & Co.
  3.6.2 Galvus (vildagliptin) - Novartis
  3.6.3 Onglyza (saxagliptin) - Bristol-Myers Squibb/AstraZeneca
  3.6.4 Tradjenta (linagliptin) - Bristol-Myers Squibb/AstraZeneca
  3.6.5 Zemiglo (gemigliptin) - LG Life Sciences
  3.6.6 Suganon (evogliptin) - Dong-A ST
  3.6.7 Gadret (anagliptin) - JW Pharmaceutical
  3.6.8 Nesina (alogliptin) - Takeda
  3.6.9 Tenelia (teneligliptin) - Mitsubishi Tanabe Pharma
3.7 SGLT-2 Inhibitors
  3.7.1 Forxiga (dapagliflozin) - AstraZeneca
  3.7.2 Invokana (canagliflozin) - Janssen
  3.7.3 Jardiance (empagliflozin) - Boehringer Ingelheim
  3.7.4 Suglat (ipragliflozin) - Astellas
3.8 Insulin Therapies
  3.8.1 Lantus (insulin glargine) - Sanofi
  3.8.2 Levemir (insulin detemir) - Novo Nordisk
  3.8.3 Tresiba (insulin degludec) - Novo Nordisk
  3.8.4 Toujeo (insulin glargine) - Sanofi
3.9 Comparative Efficacy and Safety of Marketed Products

4 PIPELINE ANALYSIS

4.1 Overview
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
4.3 Pipeline by Molecular Target
4.4 Promising Pipeline Molecules
  4.4.1 NN-9535 (subcutaneous semaglutide) and OG-217SC (oral semaglutide) - Novo Nordisk
  4.4.2 Ertugliflozin - Pfizer
  4.4.3 Bexagliflozin - Theracos
  4.4.4 Omarigliptin - Merck & Co.
  4.4.5 Sotagliflozin- Sanofi
4.5 Comparative Efficacy and Safety of Pipeline Products
4.6 Product Competitive Framework

5 CLINICAL TRIAL ANALYSIS

5.1 Failure Rate
  5.1.1 Overall Failure Rate
  5.1.2 Failure Rate by Phase and Molecule Type
  5.1.3 Failure Rate by Phase and Molecular Target
5.2 Clinical Trial Duration
  5.2.1 Trial Duration by Molecule Type and Stage of Development
  5.2.2 Trial Duration by Molecular Target and Stage of Development
5.3 Clinical Trial Size
  5.3.1 Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development
  5.3.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development
5.4 Summary of Clinical Trial Metrics

6 MULTI-SCENARIO FORECAST

6.1 Geographical Markets
6.2 South-East Asia Markets
6.3 South Korea
  6.3.1 Treatment Usage Patterns
  6.3.2 Annual Cost of Therapy
  6.3.3 Market Size
6.4 Singapore
  6.4.1 Treatment Usage Patterns
  6.4.2 Annual Cost of Therapy
  6.4.3 Market Size
6.5 Taiwan
  6.5.1 Treatment Usage Patterns
  6.5.2 Annual Cost of Therapy
  6.5.3 Market Size
6.6 Malaysia
  6.6.1 Treatment Usage Patterns
  6.6.2 Annual Cost of Therapy
  6.6.3 Market Size
6.7 Philippines
  6.7.1 Treatment Usage Patterns
  6.7.2 Annual Cost of Therapy
  6.7.3 Market Size
6.8 Thailand
  6.8.1 Treatment Usage Patterns
  6.8.2 Annual Cost of Therapy
  6.8.3 Market Size
6.9 Vietnam
  6.9.1 Treatment Usage Patterns
  6.9.2 Annual Cost of Therapy
  6.9.3 Market Size
6.10 Indonesia
  6.10.1 Treatment Usage Patterns
  6.10.2 Annual Cost of Therapy
  6.10.3 Market Size

7 DRIVERS AND BARRIERS

7.1 Drivers
  7.1.1 Aging Population, Increasing Obesity and Growing Economy
  7.1.2 Increasing Awareness of T2DM
  7.1.3 Continued Uptake of Recently Approved Drug Classes
  7.1.4 Promising Late-Stage Pipeline Products Can Change the Treatment Paradigm
  7.1.5 Enhanced Usage of Combination Therapies
7.2 Barriers
  7.2.1 Non-pharmacological First-line Treatment
  7.2.2 Widespread Usage of Generic Drugs
  7.2.3 Poor Adherence to Treatment Regimens
  7.2.4 Generic Erosion Resulting from Patent Expirations

8 DEALS AND STRATEGIC CONSOLIDATIONS

8.1 Licensing Deals
  8.1.1 Deals by Region and Value
  8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
  8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
  8.1.4 Key Licensing Deals
8.2 Co-development Deals
  8.2.1 Deals by Region and Value
  8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
  8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
  8.2.4 Key Co-development Deals

9 APPENDIX

9.1 All Pipeline Drugs by Stage of Development
  9.1.1 Discovery
  9.1.2 Preclinical
  9.1.3 IND/CTA-filed
  9.1.4 Phase I
  9.1.5 Phase II
  9.1.6 Phase III
  9.1.7 Pre-registration
9.2 Summary of Multi-Scenario Market Forecasts to 2023
  9.2.1 South-East Asia
  9.2.2 South Korea
  9.2.3 Singapore
  9.2.4 Taiwan
  9.2.5 Malaysia
  9.2.6 Philippines
  9.2.7 Thailand
  9.2.8 Vietnam
  9.2.9 Indonesia
9.3 Bibliography
9.4 Abbreviations
9.5 Research Methodology
  9.5.1 Secondary Research
  9.5.2 Marketed Product Profiles
  9.5.3 Late-Stage Pipeline Candidates
  9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
  9.5.5 Product Competitiveness Framework
  9.5.6 Pipeline Analysis
  9.5.7 Forecasting Model
  9.5.8 Deals Data Analysis
9.6 Contact Us
9.7 Disclaimer

LIST OF TABLES

Table 1: Dose Levels for Groups Initially Receiving Metformin in Combination with Glyburide, Metformin Monotherapy and Glyburide Monotherapy
Table 2: T2DM Therapeutics Market, Global, Licensing Deals Valued over $50m, 2006-April 2017
Table 3: T2DM Therapeutics Market, Global, Licensing Deals Valued over $100m, 2006-April 2017
Table 4: T2DM Therapeutics, Global, All Pipeline Products, Discovery, April 2017
Table 5: T2DM Therapeutics, Global, All Pipeline Products, Preclinical, April 2017
Table 6: T2DM Therapeutics, Global, All Pipeline Products, IND/CTA-filed, April 2017
Table 7: T2DM Therapeutics, Global, All Pipeline Products, Phase I, April 2017
Table 8: T2DM Therapeutics, Global, All Pipeline Products, Phase II, April 2017
Table 9: T2DM Therapeutics, Global, All Pipeline Products, Phase III, April 2017
Table 10: T2DM Therapeutics, Global, All Pipeline Products, Pre-registration, April 2017
Table 11: T2DM Therapeutics Market, South-East Asia, Market Forecast, 2016-2023
Table 12: T2DM Therapeutics Market, South Korea, Market Forecast, 2016-2023
Table 13: T2DM Therapeutics Market, Singapore, Market Forecast, 2016-2023
Table 14: T2DM Therapeutics Market, Taiwan, Market Forecast, 2016-2023
Table 15: T2DM Therapeutics Market, Malaysia, Market Forecast, 2016-2023
Table 16: T2DM Therapeutics Market, Philippines, Market Forecast, 2016-2023
Table 17: T2DM Therapeutics Market, Thailand, Market Forecast, 2016-2023
Table 18: T2DM Therapeutics Market, Vietnam, Market Forecast, 2016-2023
Table 19: T2DM Therapeutics Market, Indonesia, Market Forecast, 2016-2023
Table 20: Abbreviations

LIST OF FIGURES

Figure 1: T2DM Therapeutics Market, Comparative Efficacy and Safety Heatmap for Conventional Anti-diabetic Marketed Products
Figure 2: T2DM Therapeutics Market, Comparative Efficacy and Safety Heatmap for GLP-1 Receptor
Figure 3: T2DM Therapeutics Market, Comparative Efficacy and Safety Heatmap for DPP-4 inhibitors
Figure 4: T2DM Therapeutics Market, Comparative Efficacy and Safety Heatmap for SGLT-2 Inhibitors
Figure 5: T2DM Therapeutics Market, Comparative Efficacy and Safety Heatmap for Insulin Therapy
Figure 6: T2DM Therapeutics Market, Global, Pipeline, 2017
Figure 7: T2DM Therapeutics Market, Global, Pipeline by Molecular Target, 2017
Figure 8: T2DM Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2017
Figure 9: T2DM Therapeutics Market, South-East Asia, NN-9535 Forecast ($m), 2018-2023
Figure 10: T2DM Therapeutics Market, South-East Asia, OG-217SC Forecast ($m), 2020-2023
Figure 11: T2DM Therapeutics Market, South-East Asia, Ertugliflozin Forecast ($m), 2018-2023
Figure 12: T2DM Therapeutics Market, South-East Asia, Bexagliflozin Forecast ($m), 2020-2023
Figure 13: T2DM Therapeutics Market, South-East Asia, Omarigliptin Forecast ($m), 2017-2023
Figure 14: T2DM Therapeutics Market, South-East Asia, Sotagliflozin Forecast ($m), 2021-2023
Figure 15: T2DM Therapeutics Market, South-East Asia, Heatmap for Pipeline Products, April 2017
Figure 16: T2DM Therapeutics Market, South-East Asia, Competitor Matrix for Marketed and Pipeline Products, April 2017
Figure 17: T2DM Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2006-2017
Figure 18: T2DM Therapeutics, Global, Clinical Trial Failure Rate by Molecule Type, 2006-2017
Figure 19: T2DM Therapeutics, Global, Clinical Trial Failure Rate by Molecular Target, 2006-2017
Figure 20: T2DM Therapeutics, Global, Clinical Trial Duration by Phase and Molecule Type, 2006-2017
Figure 21: T2DM Therapeutics, Global, Clinical Trial Duration by Phase and Molecular Target, 2006-2017
Figure 22: T2DM Therapeutics, Global, Clinical Trial Size per Product by Stage of Development and Molecule Type, 2006-2017
Figure 23: T2DM Therapeutics, Global, Clinical Trial Size per Product by Stage of Development and Molecular Target, 2006-2017
Figure 24: T2DM Therapeutics, Global, Clinical Trial Size per Individual Trial by Molecule Type (participants), 2006-2017
Figure 25: T2DM Therapeutics, Global, Clinical Trial Size per Individual Trial by Molecular Target (participants), 2006-2017
Figure 26: T2DM Therapeutics, Global, Comparison of Average Trial Metrics by Phase and Molecular Type
Figure 27: T2DM Therapeutics, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
Figure 28: T2DM Therapeutics Market, South-East Asia, Treatment Usage Patterns (million), 2016-2023
Figure 29: T2DM Therapeutics Market, South-East Asia, Market Size ($bn), 2016-2023
Figure 30: T2DM Therapeutics Market, South Korea, Treatment Usage Patterns (million), 2016-2023
Figure 31: T2DM Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2016-2023
Figure 32: T2DM Therapeutics Market, South Korea, Market Size ($m), 2016-2023
Figure 33: T2DM Therapeutics Market, Singapore, Treatment Usage Patterns (million), 2016-2023
Figure 34: T2DM Therapeutics Market, Singapore, Annual Cost of Therapy ($), 2016-2023
Figure 35: T2DM Therapeutics Market, Singapore, Market Size ($m), 2016-2023
Figure 36: T2DM Therapeutics Market, Taiwan, Treatment Usage Patterns (million), 2016-2023
Figure 37: T2DM Therapeutics Market, Taiwan, Annual Cost of Therapy ($), 2016-2023
Figure 38: T2DM Therapeutics Market, Taiwan, Market Size ($m), 2016-2023
Figure 39: T2DM Therapeutics Market, Malaysia, Treatment Usage Patterns (million), 2016-2023
Figure 40: T2DM Therapeutics Market, Malaysia, Annual Cost of Therapy ($), 2016-2023
Figure 41: T2DM Therapeutics Market, Malaysia, Market Size ($m), 2016-2023
Figure 42: T2DM Therapeutics Market, Philippines, Treatment Usage Patterns (million), 2016-2023
Figure 43: T2DM Therapeutics Market, Philippines, Annual Cost of Therapy ($), 2016-2023
Figure 44: T2DM Therapeutics Market, Philippines, Market Size ($m), 2016-2023
Figure 45: T2DM Therapeutics Market, Thailand, Treatment Usage Patterns (million), 2016-2023
Figure 46: T2DM Therapeutics Market, Thailand, Annual Cost of Therapy ($), 2016-2023
Figure 47: T2DM Therapeutics Market, Thailand, Market Size ($m), 2016-2023
Figure 48: T2DM Therapeutics Market, Vietnam, Treatment Usage Patterns (million), 2016-2023
Figure 49: T2DM Therapeutics Market, Vietnam, Annual Cost of Therapy ($), 2016-2023
Figure 50: T2DM Therapeutics Market, Vietnam, Market Size ($m), 2016-2023
Figure 51: T2DM Therapeutics Market, Indonesia, Treatment Usage Patterns (million), 2016-2023
Figure 52: T2DM Therapeutics Market, Indonesia, Annual Cost of Therapy ($), 2016-2023
Figure 53: T2DM Therapeutics Market, Indonesia, Market Size ($m), 2016-2023
Figure 54: T2DM Therapeutics, Global, Licensing Deals by Region and Value, 2006- April 2017
Figure 55: T2DM Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006- April 2017
Figure 56: T2DM Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-April 2017
Figure 57: T2DM Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006- April 2017
Figure 58: T2DM Therapeutics Market, Global, Licensing Deals by Molecular Target and Aggregate Deal Value ($m), 2006-April 2017
Figure 59: T2DM Therapeutics Market, Global, Co-development Deals by Value ($m), 2006-April 2017
Figure 60: T2DM Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Payment Value ($m), 2006- April 2017
Figure 61: T2DM Therapeutics Market, Global, Co-development Deals by Deal Value ($m), Upfront Payment Value ($m) and Stage of Development, 2006-April 2017
Figure 62: T2DM Therapeutics Market, Global, Co-development Deals by Stage of Development, Molecule Type and Aggregate Deal Value ($bn), 2006-April 2017
Figure 63: T2DM Therapeutics Market, Global, Co-development Deals by Molecular Target and Aggregate Deal Value ($m), 2006-April 2017


More Publications